Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
about
Structured telephone support or telemonitoring programmes for patients with chronic heart failureRosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspectiveAre statins diabetogenic?Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trialCanadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trialsReview of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reductionLDL electronegativity index: a potential novel index for predicting cardiovascular diseaseThe effect of statins on average survival in randomised trials, an analysis of end point postponementCurrent strategies for preventing renal dysfunction in patients with heart failure: a heart failure stage approachLipid-lowering therapy: who can benefit?Statins in heart failure: do we need another trial?Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trialsLower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysisEfficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trialsRole of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee RecommendationsLipids, statins, and clinical outcomes in heart failure: rethinking the data.A comparison of risk factors for mortality from heart failure in Asian and non-Asian populations: an overview of individual participant data from 32 prospective cohorts from the Asia-Pacific Region.All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trial.Statins in heart failure: retrospective cohort study using routine primary care data.New data on the clinical impact of exercise training, fish oils, and statins in heart failure.The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial.Prognostic value of chromogranin A in chronic heart failure: data from the GISSI-Heart Failure trial.The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences.Diabetes and cardiovascular disease: from evidence to clinical practice - position statement 2014 of Brazilian Diabetes Society.Atherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol.Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients--a systematic review and meta-analysis.Statins and dilated cardiomyopathy: do we have enough data?Sympathoinhibitory effect of statins in chronic heart failure.Pharmacological Treatment of Heart Failure with Preserved Ejection FractionCase management for patients with chronic systolic heart failure in primary care: the HICMan exploratory randomised controlled trial.Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBStatins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trialsCoronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure.Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.Benefits of statin therapy and compliance in high risk cardiovascular patients.Statins and myocardial remodelling: cell and molecular pathways.
P2860
Q24236592-A547E842-67E1-43CF-80E6-3BB28C7AF770Q24594814-E380AAEA-008C-4769-908F-2E210C8E02D0Q24630205-1A53ACFD-CE01-4F60-9D0F-C05E82B70096Q24632679-2A4A8E9F-D448-4C45-A2F0-0B10EDEBD7FFQ24650348-01CB10C1-ABA2-40E4-BCC5-48C40C99DDE0Q26746907-8DB25A85-875B-4EB2-BFCC-4994E3DF143BQ26747559-B7F99E37-FE8F-469C-8DD1-99910C7CB3FFQ26752950-1C09676B-DA27-4286-BC24-7D5067FB8904Q26781851-CC24F30C-62FE-46EE-B4B4-BED7BACBAF1BQ26786733-52AB024E-55F7-4A90-9A15-C501028C8C30Q26822842-713492CC-5E01-43C8-A490-A479F0B95A08Q26827432-4096C822-C2D1-49F7-AE4F-EBC10F14D07EQ26998966-17602220-C9A8-47D3-AD03-E78F2540A1E5Q28483807-90495A78-F336-4C4B-83A3-A72F48BE8780Q28541942-26B81AE3-A27E-43A8-A99E-F765956991C8Q29617910-4F8C2298-BA28-4D77-88EE-AED1FD8AAB27Q29994487-E391090A-B4E8-495C-8017-A98F03E4E347Q30752824-CA8CE027-5A80-4825-AB62-D06EF0046F9CQ30828094-64287AC8-8242-4AEE-8391-19152855290BQ31101617-9CA4EB68-9346-42C8-96AD-13B88F4670BAQ31152172-C8F5D233-EF8D-48D5-91F6-D676FFECBB7AQ33466897-1266BF9A-180C-459E-99B8-5DB574BEB658Q33521834-0FFCBDA7-686E-4F04-92DE-CE6382FC21CDQ33526184-431004AC-0048-483D-88A9-0CD5CE10E79FQ33554096-B2185D69-BCE4-451E-987D-953860270F8EQ33571213-0A761315-0DF4-4D62-AC93-CC126BE52BF9Q33647298-778F4055-243C-4001-921D-0EE87276518EQ33724722-0E6C7931-E0B9-4E52-BD3C-3DCA7F3AD753Q33776201-4AF0A62F-5786-456D-BFFB-A4F765C4C8F6Q33787152-55773CF5-665C-44F0-A624-13D1F00F44ECQ33807131-DA154019-EE01-4336-A205-015F941DCA0DQ33885952-77530122-4017-48C4-929B-0FA1600364F1Q33900456-BDAA9DF3-9647-4151-B1AC-61065D0A2801Q33908782-B98680CD-75AD-45D1-8032-E6F6EBA19FA6Q34086279-31F308EA-52EF-405E-91D7-2B0BC31C265FQ34138645-3E055D46-50F4-411F-99D6-2929B94D6D89Q34142678-4609287A-B3BD-4DAE-A7B6-CCCA2BA7C230Q34169725-63E97D08-BEF9-4C75-A012-1E2F8E156A20Q34187551-4CC0D68C-8F3D-4EAF-AD97-CE64236BB530Q34196628-7139F8BA-5CAE-4391-8585-41F774EFCBBD
P2860
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Effect of rosuvastatin in pati ...... ind, placebo-controlled trial.
@ast
Effect of rosuvastatin in pati ...... ind, placebo-controlled trial.
@en
Effect of rosuvastatin in pati ...... ind, placebo-controlled trial.
@nl
type
label
Effect of rosuvastatin in pati ...... ind, placebo-controlled trial.
@ast
Effect of rosuvastatin in pati ...... ind, placebo-controlled trial.
@en
Effect of rosuvastatin in pati ...... ind, placebo-controlled trial.
@nl
prefLabel
Effect of rosuvastatin in pati ...... ind, placebo-controlled trial.
@ast
Effect of rosuvastatin in pati ...... ind, placebo-controlled trial.
@en
Effect of rosuvastatin in pati ...... ind, placebo-controlled trial.
@nl
P2093
P921
P1433
P1476
Effect of rosuvastatin in pati ...... ind, placebo-controlled trial.
@en
P2093
Donata Lucci
Gian Luigi Nicolosi
Gianni Tognoni
Gissi-HF Investigators
Maria Grazia Franzosi
Maurizio Porcu
Roberto Latini
Roberto Marchioli
Simona Barlera
P304
P356
10.1016/S0140-6736(08)61240-4
P407
P577
2008-08-29T00:00:00Z